Xtandi Today & Tomorrow

Medivation, the pharmaceutical company that owns Xtandi (formerly known as MDV-3100), the new androgen receptor antagonist to treat castrate resistant advanced prostate cancer has a number of active clinical trials, despite the fact that it has already been approved for use. The current FDA approval is specific; it has been approved for men who are [...]

Radium-223 (Alpharedin) Improves Survival in Men with Metastatic Prostate Cancer

At the October 28 meeting of the American Society for Radiation the final data from the ALSYMPCA trial were presented. The trial evaluated radium-223 (Alpharedin) in men with castrate-resistant prostate cancer that had spread to the bones. Alpharedin is part of a class of drugs called alpha-particle emitters that targets bone metastases. The good news [...]

So, Where Is Your Evidence – Is Our Propensity to Believe the Folk Law Wasting our Time & Money

Having hot flashes because of hormone deprivation therapy (ADT)? All of us dealing with advanced prostate cancer will be on ADT, it is the usual first line of therapy and it will continue until we die. Men who elect to have radiation to treat prostate cancer as their primary treatment modality will often have some [...]

CAM Supplements – Do They Work for Men with Advanced Prostate Cancer?

Many of us use supplements as either complementary or alternative medicines (CAMS) to treat our prostate cancer as well as advanced prostate cancer. If we interview a selection of men and ask what supplements they take there are a number of items we take that are fairly universal among us. They include pomegranate extract, green [...]

Elective Radiation of Pelvic Lymph Nodes During Salvage Radiotherapy Post Prostatectomy – Does It Work?

When facing a post prostatectomy biochemical failure (PSA only failure) the best way to treat is still not known. Preliminary data from Johns Hopkins [1] and Duke Universities[2] have recently provided some of the earliest evidence that salvage radiotherapy may prolong overall survival versus delay of intervention until time of symptomatic progression. Despite [...]

Go to Top